Arteriovenous malformations, a hallmark of hereditary hemorrhagic telangiectasia, may be driven by endothelial cell-cycle acceleration via CDK6, suggesting potential for repurposing CDK6 inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results